Product NameCanine Deleted In Liver Cancer 1 (DLC1) ELISA Kit
ApplicationsELISA
Species ReactivityCanine (Canis familiaris; Dog)
Other NamesARHGAP7; FLJ21120; HP; STARD12; p122-RhoGAP; Rho-GTPase-activating protein 7|StAR-related lipid transfer (START) domain containing 12|deleted in liver cancer 1 variant 2
StorageThe stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. The loss rate was determined by accelerated thermal degradation test. Keep the kit at 37C for 4 and 7 days, and compare O.D.values of the kit kept at 37C with that of at recommended temperature. (referring from China Biological Products Standard, which was calculated by the Arrhenius equation. For ELISA kit, 4 days storage at 37C can be considered as 6 months at 2 - 8C, which means 7 days at 37C equaling 12 months at 2 - 8C).
Application Details
Detect Range:Request Information Sensitivity:Request Information Sample Type:Serum, Plasma, Other biological fluids Sample Volume: 1-200 μL Assay Time:1-4.5h Detection wavelength:450 nm
Detection Method:Sandwich Test principle:This assay employs a two-site sandwich ELISA to quantitate DLC1 in samples. An antibody specific for DLC1 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and anyDLC1 present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for DLC1 is added to the wells. After washing, Streptavidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of DLC1 bound in the initial step. The color development is stopped and the intensity of the color is measured. Product Overview:Deleted in Liver Cancer 1 is deleted in the primary tumor of hepatocellular carcinoma. It maps to 8p22-p21.3, a region frequently deleted in solid tumors. It is suggested that this gene is a candidate tumor suppressor gene for human liver cancer, as well as for prostate, lung, colorectal, and breast cancers.DLC1 is frequently inactivated in human hepatocellular carcinoma, as well as some nasopharyngeal, lung, breast, prostate, kidney, colon, uterine, ovarian, and gastric cancers. The DLC1 protein contains four major functional domains: an N-terminal sterile α motif (SAM), a serine-rich (SR) region, a Rho-GAP domain, and a C-terminal steroidogenic acute regulatory protein related lipid-transfer (START) domain. DLC1 is localized to focal adhesions located at the periphery of cells.
If you have published an article using product EK10644, please notify us so that we can cite your literature.
YES